

SUPPLEMENTARY INFORMATION

New Promising Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy

Tatyana M. Khomenko, Alexandra L. Zakharenko, Arina A. Chepanova, Ekaterina S. Ilyina, Olga D. Zakharova, Vasily I. Kaledin, Valeriy P. Nikolin, Nelly A. Popova, Dina V. Korchagina, Jóhannes Reynisson, Raina Chand, Daniel M. Ayine-Tora, Jinal Patel, Ivanhoe K. H. Leung, Konstantin P. Volcho, Nariman F. Salakhutdinov, Olga I. Lavrik

NMR ^1H and ^{13}C spectra of the compounds **3aa - 3da**, **3ab - 3db**, **3ac - 3dc** and **10a, c, d**.

Table S1. The Tdp1 inhibitory activities of compounds **3aa - 3dd** and **10a, c, d**.

Table S2. The scores for the 19 ligands docked against Tdp1.


Table S3. The molecular descriptor values for the 19 compounds.

Table S4. Definition of lead-like, drug-like and Known drug space (KDS) in terms of molecular descriptors. The values given are the maxima for each descriptor for the volumes of chemical space used.




Table S5. The calculated KDI indexes for the 19 ligands.

Supplementary Figure S1. (a) Change in intrinsic fluorescence intensity of Tdp1 (10 μM) upon the addition of compound **3ba** (25 μM , 50 μM , 75 μM , 100 μM , 150 μM and 250 μM).




Compound **3aa**




Compound **3ba**




Compound 3ea






Compound **3da**






Compound **3ab**






Compound **3bb**






Compound **3cb**






Compound **3db**




Compound **3ac**






Compound **3bc**






Compound **3cc**






Compound **3dc**



Compound **10a**



Compound **10c**



Compound **10d**






Table 1. The Tdp1 inhibitory activities of compounds **3aa** - **3dd** and **10a, c, d**.

Code	IC₅₀, μM
3aa	0.49 $\pm$ 0.14
3ba	0.62 $\pm$ 0.06
3ca	0.90 $\pm$ 0.37
3da	0.52 $\pm$ 0.05
3ab	0.41 $\pm$ 0.12
3bb	7.50 $\pm$ 0.70
3cb	0.59 $\pm$ 0.07
3db	0.91 $\pm$ 0.13
3ac	0.46 $\pm$ 0.16
3bc	0.99 $\pm$ 0.30
3cc	3.23 $\pm$ 0.35
3dc	0.59 $\pm$ 0.15
3ad	0.48 $\pm$ 0.11
3bd	1.03 $\pm$ 0.58
3cd	0.43 $\pm$ 0.05
3dd	0.59 $\pm$ 0.06
10a	4.29 $\pm$ 1.24
10c	2.40 $\pm$ 0.80
10d	3.31 $\pm$ 0.98
Fur ¹	1.20 $\pm$ 0.30

¹ Furamidine was used as a positive control.

Table 2. The scores for the 19 ligands docked against Tdp1.

	Compound	ASP	CS	GS	PLP
1	3aa	39.2	32.5	66.2	70.3
2	3ba	39.1	31.6	69.2	75.2
3	3ca	36.9	32.1	70.7	71.0
4	3da	42.6	33.9	63.9	68.3
5	3ab	37.8	32.4	70.0	68.5
6	3bb	39.3	32.5	67.8	61.9
7	3cb	39.5	34.4	73.3	73.7
8	3db	33.4	27.6	68.2	67.0
9	3ac	28.7	27.2	64.7	63.7
10	3bc	38.2	30.8	64.8	67.1
11	3cc	36.7	31.6	55.6	67.0
12	3dc	38.7	31.5	64.2	66.9
13	3ad	36.4	31.2	56.2	68.5
14	3bd	37.6	30.5	54.1	64.2
15	3cd	36.7	28.1	57.3	66.1
16	3dd	38.5	32.0	65.2	64.6
17	10a	35.7	30.0	66.9	70.7
18	10c	36.4	25.6	60.8	66.4
19	10d	38.1	31.4	60.5	68.7

Table 3. The molecular descriptor values for the 19 compounds. .


	Compound	MW	HB DONOR	HB ACCEPTOR	Log P	PSA	Rot. Bonds
1.	3aa	374.5	0	3.25	6.0	47.3	7
2.	3ba	392.5	0	3.25	6.3	47.3	7
3.	3ca	453.4	0	3.25	6.6	47.3	7
4.	3da	404.5	0	4	6.1	55.5	8
5.	3ab	386.5	0	3.25	5.7	47.3	5
6.	3bb	404.5	0	3.25	5.9	47.3	5
7.	3cb	416.5	0	4	5.8	55.5	6
8.	3db	416.6	0	4	6.1	54.1	6
9.	3ac	372.5	0	3.25	5.7	45.5	4
10	3bc	390.5	0	3.25	5.6	46.9	4
11	3cc	451.4	0	3.25	6.0	46.9	4
12	3dc	402.5	0	4	5.5	55.1	5
13	3ad	372.5	0	3.25	5.7	45.5	4
14	3bd	390.5	0	3.25	5.6	46.9	4
15	3cd	451.4	0	3.25	6.0	46.9	4
16	3dd	402.5	0	4	5.4	55.1	5
17	10a	326.4	0	3.25	4.4	47.3	4
18	10c	407.3	0	3.25	5.1	47.2	4
19	10d	358.4	0	4	4.6	55.4	5

Table 4. Definition of lead-like, drug-like and Known drug space (KDS) in terms of molecular descriptors. The values given are the maxima for each descriptor for the volumes of chemical space used.

	Lead-like Space	Drug-like Space	Known Drug Space
Molecular weight (g mol ⁻¹)	300	500	800
Lipophilicity (Log P)	3	5	6.5
Hydrogen bond donors (HD)	3	5	7
Hydrogen bond acceptors (HA)	3	10	15
Polar surface area (Å ²) (PSA)	60	140	180
Rotatable bonds (RB)	3	10	17

Table 5. The calculated KDI indexes for the 19 ligands.

	Compound	KDI_{2A}	KDI_{2B}
1	3aa	5.08	0.33
2	3ba	4.90	0.27
3	3ca	4.72	0.21
4	3da	4.94	0.28
5	3ab	5.13	0.36
6	3bb	5.07	0.33
7	3cb	5.16	0.38
8	3db	5.08	0.33
9	3ac	5.13	0.36
10	3bc	5.14	0.37
11	3cc	4.96	0.30
12	3dc	5.28	0.44
13	3ad	5.20	0.40
14	3bd	5.15	0.37
15	3cd	4.97	0.30
16	3dd	5.28	0.44
17	10a	5.32	0.47
18	10c	5.21	0.41
19	10d	5.44	0.54



Supplementary Figure S1. (a) Change in intrinsic fluorescence intensity of Tdp1 (10 μM) upon the addition of compound **3ba** (25 μM , 50 μM , 75 μM , 100 μM , 150 μM and 250 μM). The buffer composition was 20 mM Tris and 250 mM NaCl, pH 8. The excitation wavelength was 280 nm and intrinsic fluorescence was measured at 350 nm. (b) Non-linear curve fitting of the corresponding fluorescence data. The K_D was found to be $63.0 \pm 11 \mu\text{M}$. Experiment were conducted in triplicate and error shown is standard derivation.